Vasoactive intestinal peptide receptor: Difference between revisions
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 27: | Line 27: | ||
{{neuroscience-stub}} | {{neuroscience-stub}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
Latest revision as of 17:43, 18 March 2025
Vasoactive intestinal peptide receptor (VIPR) is a type of G protein-coupled receptor that binds vasoactive intestinal peptide (VIP). There are two known types of VIP receptors, VIPR1 and VIPR2, which are encoded by separate genes and have different tissue distribution.
Function[edit]
VIPR1 and VIPR2 are members of the secretin receptor family. They are activated by the neuroendocrine peptide VIP and the related peptide pituitary adenylate cyclase-activating polypeptide (PACAP). Activation of VIPR leads to increased adenylate cyclase activity and elevated levels of intracellular cyclic AMP.
Clinical significance[edit]
VIP receptors have been implicated in a variety of physiological and pathological processes. They play a role in the regulation of circadian rhythm, immune response, and vasodilation. Abnormal VIPR function has been associated with diseases such as schizophrenia, asthma, and inflammatory bowel disease.
Research[edit]
Research into VIPR function and its potential as a therapeutic target is ongoing. VIP and PACAP analogs have been developed for potential use in the treatment of inflammatory and autoimmune diseases. In addition, VIPR antagonists are being investigated for their potential use in the treatment of certain types of cancer.
See also[edit]
- Vasoactive intestinal peptide
- G protein-coupled receptor
- Secretin receptor family
- Pituitary adenylate cyclase-activating polypeptide
This GPCR-related article is a stub. You can help WikiMD by expanding it.

This article is a neuroscience stub. You can help WikiMD by expanding it!
